Ind Swift Laboratories announced robust financial performance for the quarter ended December 31, 2025, marking a significant turnaround with strong profitability and revenue growth. The pharmaceutical company's Board of Directors also approved major leadership restructuring to strengthen operational efficiency.

Financial Performance Highlights

The company demonstrated remarkable improvement in its standalone financial performance during Q3FY26. Net profit surged to ₹1074.18 lakhs compared to a loss of ₹86.19 lakhs in the corresponding quarter of the previous year, representing a complete turnaround in profitability.

For the nine-month period ended December 31, 2025, the company reported net profit of ₹2761.81 lakhs compared to ₹3799.68 lakhs in the corresponding period last year. Revenue from operations for nine months reached ₹44791.33 lakhs versus ₹40490.04 lakhs, showing consistent growth momentum.

Consolidated Results

On a consolidated basis, the company maintained strong performance with net profit of ₹953.83 lakhs for Q3FY26 compared to a loss of ₹549.22 lakhs in Q3FY25. Consolidated revenue from operations grew to ₹15085.34 lakhs from ₹12879.86 lakhs year-over-year.

Leadership Restructuring

The Board approved significant changes in key management positions effective February 1, 2026, subject to shareholder approval:

Mr. Navrattan Munjal brings over three decades of pharmaceutical industry experience and has been instrumental in defining the Group's long-term strategy and global expansion. Mr. Himanshu Jain, with 19 years of industry expertise, will focus on domestic operations including sales, manufacturing, and supply chain management. Mr. Sahil Munjal, having 18 years of experience, will lead global business operations and international partnerships.

Investment Activities

During the quarter, the company completed several significant investment transactions. The Series B debentures of Synthimed Labs Private Limited worth ₹48.00 crores were fully redeemed on December 10, 2025, with the company receiving ₹61.29 crores including principal and interest. Additionally, ₹29.11 crores was invested in India Resurgence Fund II – Scheme I under the Board's authorization of up to ₹51 crores in SEBI-registered AIFs.

Corporate Updates

The company is migrating its website from www.indswiftlabs.com to www.indswiftgroup.com , with completion expected by March 31, 2026. During the transition, all investor disclosures will continue to be available at the current investor portal. The financial results reflect the combined entity post-amalgamation of Ind-Swift Limited, which became effective August 8, 2025.

Source:

Ind-Swift Laboratories Limited has submitted its latest investor presentation to stock exchanges on January 14, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The comprehensive presentation outlines the company's strategic transformation and future growth trajectory following a historic business restructuring.

Strategic Transformation Overview

The company has successfully completed a strategic reset through the ₹1,650 crore divestment of its API & CRAMS business to Synthimed Labs Pvt. Ltd., a portfolio company of India Resurgence Fund (Bain Capital & Piramal). This decisive action has transformed the company into a net debt-free entity with a unified operational structure.

The merger of Ind-Swift Limited into Ind-Swift Laboratories Limited, effective March 31, 2024 and NCLT-approved, has created a single, streamlined, formulation-focused listed entity. The company now operates as a pure-play Finished Dosage Formulation (FDF) platform with a solid revenue base of ₹550 crores.

Business Operations and Infrastructure

Post-transformation, the company operates through two primary divisions. The International Division (Global Business Unit) maintains presence across 85+ countries with strong CMO relationships and regulated market penetration, supported by an extensive dossier pipeline. The Domestic Division covers Ethical, Generics, P2P and other segments through 260+ marketing teams covering 20,000 retailers and 25,000+ doctors.

Financial Performance and Growth Targets

The company reported steady performance in the first half of FY26. Total income increased from ₹167.32 crores in Q1 FY26 to ₹170.50 crores in Q2 FY26, representing a 1.91% growth. EBITDA improved from ₹18.18 crores to ₹19.34 crores, with EBITDA margins expanding by 47 basis points to 11.34%.

The company targets sustained expansion to double revenue by FY29, supported by high-margin segments including Ethical (76% gross margin), Own-Brand (51% gross margin) and CMO (42% gross margin). Management expects topline CAGR of 20-25%, scaling from ₹550 crores to ₹1,200+ crores by FY29.

Product Portfolio and Market Presence

The company maintains a diversified export portfolio with Fexofenadine contributing 22% of product revenue, followed by Atorvastatin at 13% and Metformin at 7%. The company has filed 1,915+ dossiers across 85+ countries with 520+ approvals received, demonstrating strong regulatory capabilities.

Upcoming product launches include partnerships with Viatris for commercial supplies starting FY27, expected to generate ₹200 crore incremental revenue impact. The pipeline includes Ibuprofen Sachet, Clarithromycin Dry Suspension, and Esomeprazole formulations across European and Australian markets.

Leadership and Strategic Vision

Chairman and Managing Director N.R. Munjal emphasized the company's transformation: "The restructuring has consolidated our capabilities across manufacturing, R&D and distribution, positioning the entire organization for scalable, capital-efficient growth. We are accelerating execution across high-growth engines by strengthening CDMO visibility through the FY27 accretive Viatriis partnership."

The presentation, available on the company's website at www.indswiftlabs.com , provides comprehensive details on the company's evolution from a diversified pharmaceutical entity to a focused formulations platform positioned for sustained growth in global markets.